


**BUSINESS OVERVIEW**

- [NanoSphere Health Sciences](#) is a nano-biotechnology company focused on providing next generation delivery of nutritive elements and medications
- The Company applies its **patented nanotechnology** to **improve the bioavailability and efficacy** of essential ingredients and medications
- A commercialized "[Evolve Formulas](#)" brand of products has been developed through multiple licensing agreements for distribution of its technology
- As a multi-award winning biotechnology company, NanoSphere brings to market **over 20 years of research & development** on nano-delivery systems


**PRODUCTS**



**PROBLEM**



**SOLUTION**



**MANAGEMENT & BOARD OF DIRECTORS**



**Robert Sutton**  
Chairman & CEO

- 25+ years of successful investment and entrepreneurial experience
- Spearheaded the growth of companies in real estate, oil and gas, venture capital, valued at \$4 billion




**David Sutton**  
President, COO, Director

- Worked in nano-technology & financial services, raised millions in funding
- Previously consulted for CeeLite Technologies, a developer of new lighting sources



**Dr. Richard Kaufman**  
Chief Science Off., Director

- Previous Co-Director of the Center for Bio-gerontology Life Extension Medical Clinic & research center in LA
- Ph.D. in BioNutritional Chemistry from the University of Brussels



**Dr. Terry Grossman**  
Chief Medical Officer

- Founder & Medical Director of the Grossman Wellness Center in Denver
- Member of the American Academy of Anti-Aging Medicine & the American Holistic Medical Association



**Victor Goncalves**  
Executive Vice President


- 15 years experience in the financial markets
- Top analyst at Harvard Management Fund (\$8B) where he consulted and evaluated financing opportunities for mining projects globally




**Jim Ewing**  
Chief Financial Off. (U.S.)

- 13+ years experience working with SEC compliance, reporting, SOX compliance and risk management
- Industry experience in life sciences, pharmaceuticals, and manufacturing

## REVENUE MODEL



## INVESTMENT HIGHLIGHTS



## CAPITAL STRUCTURE

Shares Outstanding	95,505,563
Options Outstanding	4,365,555
Warrants Outstanding	8,141,773
Fully Diluted	109,012,891
Share Price as @ June 29 <sup>th</sup> , 2018	\$0.335
Market Capitalization	\$31,994,364
Pooled Shares with a 2-year Hold Period	65,000,000
<b>Insider Ownership (Non-Diluted):</b>	<b>62%</b>


## CURRENT MARKET SIZES

	Medical & Recreational Cannabis	Pharmaceutical & OTC	Dietary Supplements	Animal Health
Commercial Application	NanoSphere Cannabinoids	NanoSphere Rx & OTC	NanoSphere Nutraceuticals	NanoSphere Animal Health
US Market Size	\$24 billion <sup>1</sup>	\$333 billion <sup>2</sup>	\$131 billion <sup>4</sup>	\$23 billion <sup>5</sup>
Canadian Market Size	\$4 billion <sup>1</sup>	\$18 billion <sup>2</sup>	\$10 billion <sup>2</sup>	\$5 billion <sup>3</sup>
Revenue Source	Product Sales & License	License & Royalty	Product Sales	License & Royalty

## FINANCIAL PROJECTIONS: CANNABIS SECTOR

Year	1	2	3	4	5
Total Units Sold	145,000	737,350	1,959,663	4,835,328	7,950,532
Total Revenue (USD)	\$2.6M	\$14.7M	\$39.1	\$96.7M	\$159.0M
Gross Profit (USD)	\$1.3M	\$8.6M	\$19.5M	\$48.3M	\$79.5M

## ROADMAP: CANNABIS SECTOR



1)  
2)  
3)  
4)  
5)

statista.com  
Trade.gov  
Report by IBISWorld  
Grandview Research  
Vetnosis